Form 4: Hypha Labs CEO, Douglass A Stone, Acquires 6 Million Shares in Two Separate Grants

Hypha Labs CEO, Douglass A Stone, received 6 million shares of common stock in two separate grants, one for services related to the sale of Digipath Labs, Inc. and the other for his appointment as CEO.

Summary

• Douglass A Stone, the Chairman, President, CEO, and CFO of Hypha Labs, Inc., has reported changes in his beneficial ownership of the company's stock.
• On January 18, 2023, Mr. Stone acquired 2,000,000 shares of common stock as a grant for services related to the sale of Digipath Labs, Inc.
• On February 29, 2024, Mr. Stone acquired an additional 4,000,000 shares of common stock as a grant related to his appointment as President and CEO.
• Both grants were acquired at a price of $0.00 per share.
• Following these transactions, Mr. Stone directly owns 7,500,000 shares of Hypha Labs, Inc. common stock.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. The stock grants are a positive sign of alignment between management and shareholders, but the late filing is a minor negative.

Positives

• The grants of shares to the CEO could be seen as an incentive and alignment of interests with shareholders.
• The grants are a form of compensation for services and leadership.

Negatives

• The Form 4 filing was late due to an administrative error.

Risks

• The late filing of the Form 4 indicates a potential weakness in internal controls or compliance procedures.
• The large number of shares granted to the CEO could potentially dilute existing shareholders if not managed carefully.

Management Comments

• The Form 4 is being filed late due to an administrative error.

Industry Context

This type of stock grant is common for executive compensation, particularly in smaller companies or startups where cash may be limited. It aligns the executive's interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Stock grants are a common form of compensation for executives in the technology and biotech industries, often used to attract and retain talent.
• The size of the grant, 6 million shares, would need to be compared to similar companies of Hypha Labs' size and stage to determine if it is within industry norms.
• Companies like Amyris, Inc. and Ginkgo Bioworks, Inc. also use stock grants as part of executive compensation packages, but the specific amounts and vesting schedules vary widely.

Stakeholder Impact

• Shareholders may view the stock grants as a positive incentive for the CEO to increase company value.
• The grants could potentially dilute existing shareholders if not managed carefully.

Key Dates

Keywords

Hypha Labs, Douglass A Stone, stock grant, beneficial ownership, Form 4, CEO, Digipath Labs, share acquisition